Business Context and Reporting Period
This Form 6-K, filed on February 28, 2022, by GlaxoSmithKline plc (GSK), announces the formal introduction of Haleon, a new independent global consumer health company. The filing details the strategy, outlook, and plans for Haleon, which is expected to demerge from GSK and list on the London Stock Exchange in July 2022. Haleon will operate as a standalone entity focusing 100% on consumer health, formed from GSK's Consumer Healthcare business following the integration of Novartis and Pfizer portfolios.
Key Financial Metrics
- Revenue: Haleon achieved sales of £9.5 billion in 2021.
- Profitability: Adjusted operating margin expanded from 19.5% to 22.8% in 2021. On a 2017 exchange rate basis, this equates to approximately 25%.
- Cash Flow: Free cash flow generated was approximately £1.5 billion in both 2020 and 2021 (excluding divestment proceeds and integration/separation costs).
- R&D Investment: £257 million in 2021, representing 2.7% of sales.
- Debt and Liquidity: Post-demerger net debt/adjusted EBITDA is expected to be up to 4.0x. The target is to reduce this to <3x by the end of 2024.
- Dividend Policy: Initial dividend expected to be at the lower end of a 30-50% payout ratio range.
Material Changes and Performance
Over the 2019-2021 period, Haleon delivered a compound annual growth rate (CAGR) of 4.4% in sales, outperforming the market despite the COVID-19 pandemic. The business has undergone significant transformation through the integration of the Novartis (2015) and Pfizer (2019) portfolios, alongside the divestment of lower-growth brands. In 2021, the business realized upgraded annual cost synergies from the Pfizer integration totaling approximately £600 million, which is £100 million higher than previously announced. E-commerce sales have doubled in the last two years, with strong outperformance in China.
Guidance, Outlook, and Risks
Outlook and Guidance
- 2022 Growth: Haleon expects organic sales growth in the range of 4-6% for 2022.
- Medium-Term Targets: Annual organic sales growth of 4-6% and sustainable moderate expansion of adjusted operating margin.
- Margin Drivers: 2022 margins are expected to benefit from operating leverage, price increases realized in 2021, and approximately £120 million of synergy delivery. These are expected to offset new standalone costs of £175-200 million.
- Capital Allocation: Priorities include investing in growth, delivering shareholder returns via dividends, and pursuing strategic M&A.
Risks and Contingencies
The filing includes a cautionary statement regarding forward-looking statements. Key risks include potential interruptions to product supply, material litigation or investigation costs, changes in regulatory frameworks, and the impacts of the COVID-19 pandemic. The outlook assumes no material changes in pricing due to government or competitor action and the successful delivery of the separation program. The financial information presented differs from historical GSK segment reporting due to accounting and disclosure differences under IFRS.
Investor Verification Checklist
- Verify the final terms of the demerger and the exact listing date for Haleon in July 2022.
- Confirm the final net debt/adjusted EBITDA ratio at the time of demerger (expected up to 4.0x).
- Monitor the realization of the £600 million in Pfizer integration synergies and the impact of new standalone costs.
- Review the approved dividend payout ratio by the Haleon Board.
- Assess the impact of inflationary cost pressures and supply chain costs on the 2022 margin profile.